
## တ္တေငေ

# Paul Butler

What is the interest to provide platforms for developing and sharing reproducible methods?

Springer Nature, London, UK paul.butler@springernature.com





### Research paper



#### Introduction

Describes the research question and the hypothesis to be explored



#### **Results**

Finding reports with experimental data compiled into charts or figures



#### **Discussion**

Results are interpreted in relation with published evidence



DISCUSSION 26%



#### **Method**

Experimental design of the study and list of procedures performed (protocols)





## **Research protocol**

(Springer Protocols)

INTRO 10%

#### Introduction

Describes the protocol and its range of applications

ATERIA 13%

#### **Materials**

List the compositions of all buffers, solutions and equipment needed, with quantities used and operation instructions

ETHOD 46%

#### Method

Detailed and chronological explanation of the individual stages of the technique, with timings and critical steps




NOTES 32%



#### **Notes**

Recommendations and details to implement the protocols

# Example: experimental procedure is heavily condensed in research papers





TYPE Original Research
PUBLISHED 10 November 2022
DOI 10.3389/fviro.2022.968338

#### Check for updates

#### OPEN ACCESS

Fan Zhou, University of Bergen, Norway

REVIEWD BY
Glenn Marsh,
Commonwealth Scientific and
Industrial Research Organisation
(CSIRO), Australia
Roberta Antonia Diotti,
Vita-Salute San Raffaele University,
Italy
Gary Kobinger,
Galveston National Laboratory,

United States

### Elicitation of immune responses against Nipah virus by an engineered synthetic DNA vaccine

Hyeree Choi<sup>1</sup>, Sagar B. Kudchodkar<sup>1</sup>t, Ziyang Xu<sup>1</sup>, Michelle Ho<sup>1</sup>, Peng Xiao<sup>1</sup>, Stephanie Ramos<sup>2</sup>, Laurent Humeau<sup>2</sup>, David B. Weiner<sup>1</sup> and Kar Muthumani<sup>1\*t</sup>

<sup>1</sup>Vaccine 6 Immunotherapy Center, The Wistar Institute, Philadelphia, PA, United States, <sup>2</sup>R&D, Inovio Pharmaceuticals, Plymouth Meeting, PA, United States

Six to eight-week-old female C57BL/6 mice (Charles River, USA) were used for all the experiments and were maintained in specific pathogen-free conditions (Wistar IACUC# 112785). Mice were immunized with 25µg of pVax1 empty vector or NiV-F or NiV-G plasmids into the anterior tibialis (TA) muscle,

followed by the delivery of two 0.1 Amps of triangulated squarewave pulses per insertion with 3P CELLECTRA<sup>®</sup> adaptive constant current enhanced electroporation (EP) delivery device (Inovio Pharmaceuticals, USA) as described previously (28).

